Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents

Despite major advances in hemophilia care, many patients continue to experience breakthrough bleeding, progressive joint morbidity, inhibitor development, and substantial treatment burden. To help more individuals achieve active, unrestricted lives, health care professionals must move beyond traditional prophylaxis targets by applying evolving evidence on factor VIII (FVIII) levels, optimizing prophylaxis to provide sustained bleed protection, and individualizing therapy to meet patients' needs, preferences, and real‐world considerations. This 3‐segment podcast features expert discussions on optimizing joint health across the lifespan, including subclinical bleeding and imaging‐based monitoring; applying current and emerging guidance on FVIII targets and factor‐based strategies; and integrating rebalancing agents into practice, with a focus on clinical outcomes, safety and risk mitigation, treatment burden, patient selection, and individualized hemophilia management. To view this activity and obtain CME/CE credit, visit http://www.cmeologyce.org/ajhhemophiliapodcast .